Jacobio Pharma's glecirasib demonstrated a confirmed objective response rate (cORR) of 47.9% in second-line non-small cell lung cancer (NSCLC) patients.
Jacobio Pharma's glecirasib demonstrated a 47.9% objective response rate in KRAS G12C mutant non-small cell lung cancer (NSCLC) patients in a pivotal phase II trial.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.